Peginterferon for chronic hepatitis B: Predicting success with on-treatment benchmarks

被引：7
|
作者：
Moucari, Rami [1 ,2 ]
机构：
[1] Hop Beaujon, Serv Hepatol, F-92110 Clichy, France
[2] Hop Beaujon, INSERM, U773, F-92110 Clichy, France
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2010年 / 25卷 / 09期
关键词：
SUSTAINED HBEAG; SERUM HBSAG; INTERFERON; SEROCONVERSION; SUPPRESSION; ALPHA-2A; THERAPY;
D O I：
10.1111/j.1440-1746.2010.06372.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1474 / 1475
页数：2
相关论文
共 50 条
  • [21] Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C
    Fukuda, Kazuto
    Imai, Yasuharu
    Hiramatsu, Naoki
    Irishio, Keiko
    Igura, Takumi
    Sawai, Yoshiyuki
    Kogita, Sachiyo
    Makino, Yuki
    Mizumoto, Rui
    Matsumoto, Yasushi
    Nakahara, Masanori
    Zushi, Sinichiro
    Kajiwara, Nobuyuki
    Oze, Tsugiko
    Kawata, Sumio
    Hayashi, Norio
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2014, 44 (12) : 1165 - 1171
  • [22] Durability of Peginterferon alfa-2b Treatment at 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    Yan, Kenneth Kar-Lung
    Chim, Angel Mei-Ling
    Chan, Hoi-Yun
    Tse, Chi-Hang
    Choi, Paul Cheung-Lung
    Chan, Anthony Wing-Hung
    Sung, Joseph Jao-Yiu
    Chan, Henry Lik-Yuen
    HEPATOLOGY, 2010, 51 (06) : 1945 - 1953
  • [23] Peginterferon-α2a for the treatment of hepatitis B infection
    Cooksley, WGE
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (08) : 1373 - 1380
  • [24] A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China
    Ren, Peipei
    Li, Hu
    Huang, Yan
    Jiang, Jiayuan
    Guo, Simin
    Cao, Zhujun
    Zhang, Chenxi
    Zhou, Tianhui
    Gan, Qinyi
    Zhao, Shuang
    Chen, Lichang
    Guo, Qing
    Cai, Wei
    Wang, Hui
    Hu, Peng
    Xie, Qing
    ANTIVIRAL RESEARCH, 2021, 194
  • [25] A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B
    Chan, H. L. Y.
    Messinger, D.
    Papatheodoridis, G. V.
    Cornberg, M.
    Xie, Q.
    Piratvisuth, T.
    Ren, H.
    Kennedy, P. T.
    Thompson, A.
    Caputo, A.
    Bakalos, G.
    Pavlovic, V.
    Lampertico, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (05) : 547 - 555
  • [26] Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon
    Boglione, Lucio
    Cusato, Jessica
    Allegra, Sarah
    Esposito, Isabella
    Patti, Francesca
    Cariti, Giuseppe
    Di Perri, Giovanni
    D'Avolio, Antonio
    ANTIVIRAL RESEARCH, 2014, 102 : 35 - 43
  • [27] On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients
    Cai, Wei
    Xie, Qing
    An, Baoyan
    Wang, Hui
    Zhou, Xiaqiu
    Zhao, Guomin
    Guo, Qing
    Gu, Ruiying
    Bao, Shisan
    JOURNAL OF CLINICAL VIROLOGY, 2010, 48 (01) : 22 - 26
  • [28] Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers
    Wu, Fengping
    Lu, Rui
    Liu, Yixin
    Wang, Yikai
    Tian, Yan
    Li, Yaping
    Li, Mei
    Wang, Wenjun
    Zhang, Xin
    Jia, Xiaoli
    Dang, Shuangsuo
    LIVER INTERNATIONAL, 2021, 41 (09) : 2032 - 2045
  • [29] New molecules in the treatment of chronic hepatitis B
    Zarski, Jean-Pierre
    PRESSE MEDICALE, 2009, 38 (05): : 692 - 694
  • [30] New drugs for the treatment of chronic hepatitis B and interdisciplinary aspects of chronic hepatitis B virus infection
    Horvath, Gabor
    ORVOSI HETILAP, 2013, 154 (29) : 1142 - 1150
12345